Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rigel's return

Rigel's return

Early last year, when Rigel Pharmaceuticals Inc. found itself low on cash, a group of VCs threw it a lifeline in the form of a PIPE. With Phase II proof-of-concept data now in hand, the investors are looking at a 10X uptick

Read the full 432 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers